ScripAstraZeneca’s Phase III SERENA-6 study of camizestrant could usher in a new treatment paradigm by using biomarker testing to detect emerging resistance in breast cancer and change therapy without wait
In VivoWhen Michael Davidson, CEO of NewAmsterdam Pharma, describes his company’s lead asset obicetrapib, he frames it as a solution to one of cardiology’s most persistent challenges: managing residual cardi
ScripAs Menarini builds out its “glocalized” portfolio strategy to propel its business in the Asia-Pacific, the Italian group is also advancing efforts in digital innovation and leveraging real-world evide
ScripThe Menarini group is putting the pedal to the metal in the Asia Pacific region, with a “glocalised” approach that adapts its portfolio and pricing plank to the local market, funding and affordability